118 related articles for article (PubMed ID: 26314985)
1. Brentuximab vedotin: axonal microtubule's Apollyon.
Mariotto S; Ferrari S; Sorio M; Benedetti F; Tridente G; Cavallaro T; Gajofatto A; Monaco S
Blood Cancer J; 2015 Aug; 5(8):e343. PubMed ID: 26314985
[No Abstract] [Full Text] [Related]
2. Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):17-8. PubMed ID: 27007008
[No Abstract] [Full Text] [Related]
3. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.
Pastorelli F; Derenzini E; Plasmati R; Pellegrini C; Broccoli A; Casadei B; Argnani L; Salvi F; Pileri S; Zinzani PL
Leuk Lymphoma; 2013 Oct; 54(10):2318-21. PubMed ID: 23391144
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
[No Abstract] [Full Text] [Related]
5. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):6. PubMed ID: 27007002
[No Abstract] [Full Text] [Related]
7. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
[No Abstract] [Full Text] [Related]
8. Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):7-8. PubMed ID: 27007003
[No Abstract] [Full Text] [Related]
9. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation.
Baxley AA; Kumm DE; Bishop CB; Medina PJ; Holter-Chakrabarty J
J Oncol Pharm Pract; 2013 Sep; 19(3):279-83. PubMed ID: 23154572
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
11. Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.
Kojima M; Ogiya D; Kawai H; Miyamoto M; Ohmachi K; Ogawa Y; Nakamura N; Ando K
Acta Haematol; 2015; 134(3):181-2. PubMed ID: 26022650
[No Abstract] [Full Text] [Related]
12. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
Younes A
Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
[No Abstract] [Full Text] [Related]
14. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
15. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for Hodgkin lymphoma who had failed allogeneic stem cell transplantation: a multicenter retrospective study.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):12-4. PubMed ID: 25768995
[No Abstract] [Full Text] [Related]
17. Classical Hodgkin's lymphoma: past, present and future perspectives.
Eyre TA; King AJ; Collins GP
Br J Hosp Med (Lond); 2013 Nov; 74(11):612-8. PubMed ID: 24220522
[No Abstract] [Full Text] [Related]
18. [Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation].
Meshitsuka S; Suzuki K; Igeta Y; Kawai S; Kumasaka T; Tsukada N
Rinsho Ketsueki; 2015 Jun; 56(6):699-704. PubMed ID: 26256882
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
